Visual System Abnormalities in Adrenomyeloneuropathy
Ann Neurol 37:550-552, Kaplan,P.W.,et al, 1995
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Lidocaine Unmasks Silent Demyelinative Lesions in Multiple Sclerosis
Neurol 42:2088-2093, Sakurai,M.,et al, 1992
Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Hallervorden-Spatz Syndrome and Brain Iron Metabolism
Arch Neurol 48:1285-1293, Swaiman,K.F., 1991
Vision and Hearing During Deferoxamine Therapy
J Pediatr 117:326-330, Cohen,A.,et al, 1990
Optic Neuritis:A Prospective Study
Neurol 40:919-923, Celesia,G.G.,et al, 1990
Visual & Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
NEJM 314:869-873, Olivieri,N.F.,et al, 1986
Carotid Occlusive Disease, Effect of Bright Light on Visual Evoked Response
Arch Neurol 39:687-689, Donnan,G.A.,et al, 1982
Evoked Potentials In Clinical Medicine, (First of Two Parts)
NEJM 306:1140-1150, Chiappa,K.H.,et al, 1982
Toluene Optic Neuropathy
Ann Neurol 4:390, Keane,J.R., 1978